11.06.26 -- Building Sustainable Biopharma Supply Chains Starts With Procurement

Explore the differences between liquid nitrogen and mechanical cryogenic freezers, as well as how each method supports scientific, medical, and industrial storage needs.

See why single-use cold-chain containers made with polytetrafluoroethylene fluoropolymers may be less susceptible to failure and breakage at cold temperatures.

Facility-level and spend-based carbon accounting leave critical gaps in biopharma Scope 3 management. Examine how batch-level product carbon footprinting changes what's measurable and what's actionable.

Early choices in capping strategy, IVT conditions, raw materials, and downstream design shape yield, cost, and quality in mRNA manufacturing, and can determine whether a cGMP campaign succeeds.

Immediate, quantifiable verification replaces seven-day incubation periods. Discover how enzyme-based indicators optimize hydrogen peroxide decontamination.

Technology can transform the entire biopharma production process chain. Using integrated process models, machine learning, and genetic algorithms has made production faster and more efficient.

The peptide manufacturing industry is evolving to meet the demands of efficiency, scalability, and sustainability. Learn how the latest innovations are addressing these challenges.

In cell processing, rigid, single-function equipment can lead to inefficiencies, wasted space, and scheduling conflicts. A versatile approach can help teams do more with less.

Investigations into viable air excursions are difficult to perform using traditional methods. Uncover why a real-time viable particle counter is key to providing process improvement.

Gene therapy developers are accelerating timelines with platform approaches, DoE, stronger development-manufacturing alignment, and PAT tools to reach late-phase manufacturing faster.

Early risk assessment, leaner scale-down model qualification, and tighter process characterization scope offer the clearest time savings in microbial filings, each with scientific trade-offs worth weighing.

Compare leading protein expression platforms and see how complexity, scalability, cost, and quality shape the path to commercial production.

When research, manufacturing, and supply operate in silos, every phase transition resets alignment. Here, the authors observe what changes when those functions operate within a shared framework.

Middlesex County, NJ, is a premier life sciences hub, attracting major biopharma leaders, entrepreneurs, and investors to accelerate global medical innovation.

With tox material in hand as soon as possible, antibody-derived drug developers can conduct their tox studies earlier, facilitating a timely IND submission and speeding up pathways to patients.

To ensure the commercial success of cell therapies, developers must adopt innovative manufacturing and QC technologies that reduce COGS while enhancing scalability, quality, and clinical outcomes.

Disease modeling has evolved well beyond animal studies, and understanding which platform fits which research question is now a critical skill for modern biology teams.

Find out how early integration of cell line engineering, process development, and analytics compressed a complex antibody program from DNA to drug substance bulk fill in just 8.5 months.

Delve into the automated production of protein microparticles using an innovative method that offers a standardized and scalable solution for co-precipitation in biopolymer particle fabrication.

Gain insight into designing large Design-of-Experiment (DOE) upstream process development studies and the elements that could positively or negatively effect your throughput.

Magnetic tweezer experiments often seek to measure changes in the extension or relaxation of a polymer, a functionality useful, for example, in exploring how different enzymes manipulate polymer structures.